<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2017.01499</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Gene Expression in Class 2 Integrons Is SOS-Independent and Involves Two Pc Promoters</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jov&#x00E9;</surname> <given-names>Thomas</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/423328/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Da Re</surname> <given-names>Sandra</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tabesse</surname> <given-names>Aurore</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gassama-Sow</surname> <given-names>Amy</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/277324/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ploy</surname> <given-names>Marie-C&#x00E9;cile</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/289791/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>INSERM, CHU Limoges, UMR 1092, Universit&#x00E9; Limoges</institution> <country>Limoges, France</country></aff>
<aff id="aff2"><sup>2</sup><institution>Unit&#x00E9; de Bact&#x00E9;riologie Exp&#x00E9;rimentale, Institut Pasteur de Dakar</institution> <country>Dakar, Senegal</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: <italic>Manuela Cani&#x00E7;a, Instituto Nacional de Sa&#x00FA;de, Portugal</italic></p></fn>
<fn fn-type="edited-by"><p>Reviewed by: <italic>Alfonso Soler-Bistue, Institut Pasteur, France; Nicolas Carraro, University of Lausanne, Switzerland; Ashima Kushwaha Bhardwaj, Indian Institute of Advanced Research, India</italic></p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x002A;Correspondence: <italic>Thomas Jov&#x00E9;, <email>thomas.jove@unilim.fr</email></italic></p></fn>
<fn fn-type="other" id="fn002"><p>This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology</p></fn></author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>08</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>08</volume>
<elocation-id>1499</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>03</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>07</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2017 Jov&#x00E9;, Da Re, Tabesse, Gassama-Sow and Ploy.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Jov&#x00E9;, Da Re, Tabesse, Gassama-Sow and Ploy</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Integrons are powerful bacterial genetic elements that permit the expression and dissemination of antibiotic-resistance gene cassettes. They contain a promoter Pc that allows the expression of gene cassettes captured through site-specific recombination catalyzed by IntI, the integron-encoded integrase. Class 1 and 2 integrons are found in both clinical and environmental settings. The regulation of <italic>intI</italic> and of Pc promoters has been extensively studied in class 1 integrons and the regulatory role of the SOS response on <italic>intI</italic> expression has been shown. Here we investigated class 2 integrons. We characterized the P<italic>intI2</italic> promoter and showed that <italic>intI2</italic> expression is not regulated via the SOS response. We also showed that, unlike class 1 integrons, class 2 integrons possess not one but two active Pc promoters that are located within the <italic>attI2</italic> region that seem to contribute equally to gene cassette expression. Class 2 integrons mostly encode an inactive truncated integrase, but the rare class 2 integrons that encode an active integrase are associated with less efficient Pc2 promoter variants. We propose an evolutionary model for class 2 integrons in which the absence of repression of the integrase gene expression led to mutations resulting in either inactive integrase or Pc variants of weaker activity, thereby reducing the potential fitness cost of these integrons.</p>
</abstract>
<kwd-group>
<kwd>integrons</kwd>
<kwd>SOS response</kwd>
<kwd>promoter</kwd>
<kwd>antibiotic resistance</kwd>
<kwd>regulation</kwd>
</kwd-group>
<contract-num rid="cn001">FRM DEQ20150331742</contract-num>
<contract-sponsor id="cn001">Fondation pour la Recherche M&#x00E9;dicale<named-content content-type="fundref-id">10.13039/501100002915</named-content></contract-sponsor>
<counts>
<fig-count count="6"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="35"/>
<page-count count="11"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec><title>Introduction</title>
<p>Integrons are widely used by Gram-negative bacteria to resist antibiotics. These DNA elements can acquire, exchange and express promoterless coding sequences embedded within gene cassettes (<xref ref-type="bibr" rid="B13">Escudero et al., 2015</xref>). The integron functional platform is composed of a gene (<italic>intI</italic>) that encodes a site-specific recombinase (IntI); a recombination site (<italic>attI</italic>); and a functional promoter (Pc), divergently oriented to the integrase gene, that allows the expression of gene cassettes (<xref ref-type="bibr" rid="B34">Stokes and Hall, 1989</xref>). IntI catalyzes recombination events that lead either to the incorporation of gene cassettes within the integron, or to their excision. Several integron classes can be discriminated on the basis of their IntI sequences (<xref ref-type="bibr" rid="B8">Collis et al., 2002</xref>). In clinical settings, five integron classes involved in the expression and dissemination of antibiotic-resistance gene cassettes have been described. Class 1 integrons prevail in most epidemiological studies in human and animals, followed by class 2 integrons (<xref ref-type="bibr" rid="B17">Gillings, 2014</xref>).</p>
<p>In class 1 integrons, hundreds of distinct gene cassette arrays have been described (<xref ref-type="bibr" rid="B27">Moura et al., 2009</xref>). Class 2 integrons are associated with transposons related to Tn<italic>7</italic> (<xref ref-type="bibr" rid="B5">Cambray et al., 2010</xref>) and usually carry three resistance-encoding cassettes designated <italic>dfrA1</italic>, <italic>sat2</italic> and <italic>aadA1</italic> (encoding resistance to trimethoprim, streptothricin and streptomycin/spectinomycin, respectively), followed by a pseudocassette of unknown function (<italic>orfX</italic>, also known as <italic>ybeA</italic>) (<bold>Figure <xref ref-type="fig" rid="F1">1A</xref></bold>) (<xref ref-type="bibr" rid="B19">Hall and Stokes, 1993</xref>). Variations in this gene cassette array have rarely been described (<xref ref-type="bibr" rid="B4">Biskri and Mazel, 2003</xref>; <xref ref-type="bibr" rid="B1">Ahmed et al., 2005</xref>; <xref ref-type="bibr" rid="B30">Ram&#x00ED;rez et al., 2005</xref>, <xref ref-type="bibr" rid="B29">2010</xref>; <xref ref-type="bibr" rid="B3">Barlow and Gobius, 2006</xref>; <xref ref-type="bibr" rid="B12">Dubois et al., 2007</xref>; <xref ref-type="bibr" rid="B16">Gassama Sow et al., 2008</xref>; <xref ref-type="bibr" rid="B24">M&#x00E1;rquez et al., 2008</xref>). This low diversity of the gene cassette array is thought to be due to disruption of the integrase gene <italic>intI2</italic> by an internal ochre STOP codon (TAA) at position 179, yielding an inactive 178-aa polypeptide (<xref ref-type="bibr" rid="B20">Hansson et al., 2002</xref>) (<bold>Figure <xref ref-type="fig" rid="F1">1A</xref></bold>). Few class 2 integrons with a non-disrupted <italic>intI2</italic> gene encoding a 325-aa full-length functional integrase have been described (<xref ref-type="bibr" rid="B3">Barlow and Gobius, 2006</xref>; <xref ref-type="bibr" rid="B24">M&#x00E1;rquez et al., 2008</xref>; <xref ref-type="bibr" rid="B31">Rodr&#x00ED;guez-Minguela et al., 2009</xref>; <xref ref-type="bibr" rid="B35">Wei et al., 2014</xref>). A putative promoter for <italic>intI2</italic>, hereafter named P<italic>intI2</italic>, has been proposed in the annotation of the R483 plasmid (GenBank accession number <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="L10818">L10818</ext-link>, <bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>). This P<italic>intI2</italic> promoter overlaps a putative LexA repressor operator conserved in many integron classes (<xref ref-type="bibr" rid="B6">Cambray et al., 2011</xref>), suggesting that <italic>intI2</italic> could be under the control of the SOS response, like the <italic>intI1</italic> gene of class 1 integrons and <italic>intIA</italic> of the chromosomal integron of <italic>Vibrio cholerae</italic> (<xref ref-type="bibr" rid="B18">Guerin et al., 2009</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>Class 2 integrons. <bold>(A)</bold> General structure of class 2 integrons: Arrows indicate the coding sequences with the gene name above, triangles and circles are <italic>attC</italic> and <italic>attI</italic> recombination sites, respectively. The <italic>attI2</italic> region and gene cassette array are indicated. Dotted vertical bars separate each gene cassette. The putative promoters are shown as broken arrows with their names indicated. <italic>orfX</italic> is a pseudocassette whose <italic>attC</italic> site is incomplete. The star symbolizes the nonsense mutation that disrupts most <italic>intI2</italic> genes. <bold>(B)</bold> Nucleotide sequence of the <italic>attI2</italic> region. The -35 and -10 elements of the putative promoters are written in bold uppercase, and their names are indicated. The <italic>intI2</italic> START codon and its putative RBS are written in bold uppercase on the bottom strand. The transcriptional (+1) mapped for P<italic>intI2</italic> is indicated by a broken arrow and bold uppercase. The putative LexA box is represented as a dotted rectangle. The position of several nucleotides is numbered (italics).</p></caption>
<graphic xlink:href="fmicb-08-01499-g001.tif"/>
</fig>
<p>Gene cassette expression depends on the Pc promoter which, in class 1 and 3 integrons, is located within the <italic>intI</italic> coding sequence (<xref ref-type="bibr" rid="B7">Collis and Hall, 1995</xref>; <xref ref-type="bibr" rid="B8">Collis et al., 2002</xref>). In class 2 integrons, however, no Pc promoter sequence has been found within the <italic>intI2</italic> gene, and part of the <italic>attI2</italic> region seems sufficient for gene cassette expression (<xref ref-type="bibr" rid="B20">Hansson et al., 2002</xref>) (<bold>Figure <xref ref-type="fig" rid="F1">1A</xref></bold>). Four putative Pc promoters, hereafter renamed Pc2A to Pc2D, have been proposed in the sequence between the start codon of the <italic>intI2</italic> gene and the first gene cassette (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>) (<xref ref-type="bibr" rid="B32">Simonsen et al., 1983</xref>; <xref ref-type="bibr" rid="B20">Hansson et al., 2002</xref> and Genbank accession number <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="AM261760">AM261760</ext-link>). A transcriptional start site consistent with the Pc2A promoter was recently mapped (<xref ref-type="bibr" rid="B10">da Fonseca et al., 2011</xref>). However, none of these potential Pc2 promoters has been experimentally characterized.</p>
<p>The aim of this study was to examine the expression of both the integrase and the gene cassettes of class 2 integrons, and to evaluate the role of the SOS response in class 2 integrons integrase expression. We mapped the P<italic>intI2</italic> promoter and found that despite the presence of a potential LexA binding site, P<italic>intI2</italic> is not under control of the SOS response. We also found that two promoters, Pc2A and Pc2B, seem to contribute equally to the expression of gene cassettes in class 2 integrons.</p>
</sec>
<sec id="s1" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec><title>Bacteria and Growth Conditions</title>
<p>The bacterial strains and plasmids used in this study are listed in <bold>Table <xref ref-type="table" rid="T1">1</xref></bold>. Cells were grown at 37&#x00B0;C in lysogeny broth (LB) supplemented when necessary with kanamycin (Km, 25 &#x03BC;g/ml).</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Strains and plasmids used in this study.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Strains/plasmids</th>
<th valign="top" align="left">Genotype or description</th>
<th valign="top" align="left">Source or reference</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left"><bold><italic>E. coli</italic> strains</bold></td>
<td valign="top" align="left"></td>
<td valign="top" align="left"></td>
</tr>
<tr>
<td valign="top" align="left">DH5aaa</td>
<td valign="top" align="left">(F<sup>-</sup>) <italic>endA1 supE44 thi-1 recA1 relA1 gyrA96 deoR nupG</italic>&#x03D5;80 &#x0394;<italic>lacZ</italic>&#x0394;<italic>M15</italic>&#x0394; (<italic>lacZYA- argF</italic>)U169, <italic>hsdR</italic>17(rK<sup>-</sup> mK<sup>+</sup>), bbb&#x2013;</td>
<td valign="top" align="left">Laboratory collection</td>
</tr>
<tr>
<td valign="top" align="left">MG1656</td>
<td valign="top" align="left">MG1655<italic>lac</italic>-</td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B14">Esp&#x00E9;li et al., 2001</xref></td>
</tr>
<tr>
<td valign="top" align="left">MG1656&#x0394;<italic>lexA</italic></td>
<td valign="top" align="left">MG1656&#x0394;<italic>lexA</italic>&#x0394;<italic>sfiA</italic></td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B18">Guerin et al., 2009</xref></td>
</tr>
<tr>
<td valign="top" align="left">MG1656&#x0394;<italic>recA</italic></td>
<td valign="top" align="left">MG1656&#x0394;<italic>recA</italic></td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B11">Da Re et al., 2009</xref></td>
</tr>
<tr>
<td valign="top" align="left"><bold><italic>S. sonnei</italic> strain</bold></td>
<td valign="top" align="left"></td>
<td valign="top" align="left"></td></tr>
<tr>
<td valign="top" align="left">isolate Dak 0898/12-14</td>
<td valign="top" align="left">Isolate carrying a class 2 integron</td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B16">Gassama Sow et al., 2008</xref></td>
</tr>
<tr>
<td valign="top" align="left"><bold>Plasmids</bold></td>
<td valign="top" align="left"></td>
<td valign="top" align="left"></td></tr>
<tr>
<td valign="top" align="left">pAT674</td>
<td valign="top" align="left">6.5-kb <italic>Bam</italic>HI fragment from In40 class 1 integron cloned into pBGS18</td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B28">Ploy et al., 1998</xref></td>
</tr>
<tr>
<td valign="top" align="left">pSU38&#x0394;tot<italic>lacZ</italic></td>
<td valign="top" align="left">Vector carrying <italic>lacZ</italic> coding sequence with no translation initiation region nor promoter.</td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B21">Jov&#x00E9; et al., 2010</xref></td>
</tr>
<tr>
<td valign="top" align="left">pPintI2-1</td>
<td valign="top" align="left">Whole <italic>attI2</italic> region amplified with primers 1 and 2 from isolate Dak 0898-14 cloned into pSU38&#x0394;tot<italic>lacZ</italic> to obtain P<italic>intI2</italic>-<italic>lacZ</italic> fusion.</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPintI2-2</td>
<td valign="top" align="left">P<italic>intI2</italic> promoter amplified with primers 2 and 3 from isolate Dak 0898-14 cloned into pSU38&#x0394;tot<italic>lacZ</italic>.</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPintI2-3</td>
<td valign="top" align="left">-10 sequence of P<italic>intI2</italic> mutated (TAGAAT mutated into cgGAcg) in pPintI2 with primers 4 and 5.</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-1</td>
<td valign="top" align="left"><italic>attI2</italic> region + beginning of <italic>dfrA1</italic> amplified with primers 10 and 12 from isolate Dak 0898-14 cloned into pSU38&#x0394;tot<italic>lacZ</italic> to obtain Pc-<italic>lacZ</italic> translational fusion.</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-2</td>
<td valign="top" align="left">pPc2-1 plus part of <italic>intI2</italic> (PCR product amplified with primers 12 and 13)</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-3</td>
<td valign="top" align="left">pPc2-1 deleted of Pc2D (PCR product amplified with primers 12 and 14)</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-4</td>
<td valign="top" align="left">pPc2-1 deleted of Pc2D and A (PCR product amplified with primers 12 and 15)</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-5</td>
<td valign="top" align="left">pPc2-1 deleted of Pc2D, A and B (PCR product amplified with primers 12 and 16)</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-5<sup>&#x2217;</sup></td>
<td valign="top" align="left">pPc2-4 with the -10 sequence of Pc2C mutated (TAAAAT mutated into cgAAAT) with primers 24 and 25</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-6</td>
<td valign="top" align="left">pPc2-1 deleted of Pc2D, A, B and C (PCR product amplified with primers 12 and 17)</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-7</td>
<td valign="top" align="left">pPc2-1 mutated with primers 20 and 21 to inactivate Pc2A</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-8</td>
<td valign="top" align="left">pPc2-1 mutated with primers 22 and 23 to inactivate Pc2B</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-9</td>
<td valign="top" align="left">pPc2-1 mutated with primers 20/21 and 22/23 to concomitantly inactivate Pc2A and Pc2B</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-10</td>
<td valign="top" align="left">pPc2-1 mutated with primers 24 and 25 to inactivate Pc2C</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-11</td>
<td valign="top" align="left">pPc2-1 mutated with primers 26 and 27 to create the variant of Pc2A</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-12</td>
<td valign="top" align="left">pPc2-1 mutated with primers 28 and 29 to create the variant of Pc2B</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2-13</td>
<td valign="top" align="left">pPc2-1 mutated with primers 26/27 and 28/20 to concomitantly introduce the variants of both Pc2A and Pc2B</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2A</td>
<td valign="top" align="left">Pc2A amplified with primers 14 and 18 from isolate Dak 0898-14 cloned into pSU38&#x0394;tot<italic>lacZ</italic></td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2A<sup>&#x2217;</sup></td>
<td valign="top" align="left">-10 sequence of Pc2A mutated (TAAAAT into cgAgcg) in pPc2A mutated with primers 20 and 21.</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2B</td>
<td valign="top" align="left">Pc2B amplified with primers 15 and 19 from isolate Dak 0898-14 cloned into pSU38&#x0394;tot<italic>lacZ</italic>.</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2B<sup>&#x2217;</sup></td>
<td valign="top" align="left">-10 sequence of Pc2B mutated (TTTAAT mutated into TTcgAT) in pPc2B mutated with primers 22 and 23</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2A-V2</td>
<td valign="top" align="left">pPc2A mutated with primers 26 and 27 to create the second variant of Pc2A</td>
<td valign="top" align="left">This study</td>
</tr>
<tr>
<td valign="top" align="left">pPc2B-V2</td>
<td valign="top" align="left">pPc2B mutated with primers 28 and 29 to create the second variant of Pc2B</td>
<td valign="top" align="left">This study</td></tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec><title><italic>lacZ</italic> Transcriptional Fusions</title>
<p>Plasmids pPc2, pPintI2 and their derivatives were constructed by cloning, into the EcoRI&#x2013;BamHI sites of pSU38&#x0394;tot<italic>lacZ</italic> (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>), a PCR product amplified either from genomic DNA of the <italic>Shigella sonnei</italic> isolate Dak 0898/12-14 carrying a class 2 integron previously described in the lab (<xref ref-type="bibr" rid="B16">Gassama Sow et al., 2008</xref>) or by assembly PCR (see below). All cloned fragments were verified by sequencing. All oligonucleotides were purchased from Sigma&#x2013;Aldrich and are listed in Supplementary Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>. Each <italic>lacZ</italic> fusion plasmid was transformed into <italic>Escherichia coli</italic> strain MG1656 (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>).</p>
</sec>
<sec><title>Assembly PCR</title>
<p>Assembly PCR was used to mutate the Pc2 or P<italic>intI2</italic> promoter, using overlapping primers that contained the desired mutation, and two external primers, as previously described (<xref ref-type="bibr" rid="B21">Jov&#x00E9; et al., 2010</xref>).</p>
</sec>
<sec><title>5&#x2032;Rapid Amplification cDNA Ends (5&#x2032;RACE)</title>
<p>Total RNA from <italic>E. coli</italic> MG1656/pPintI2-1 (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>) was extracted and cDNA specific to the <italic>lacZ</italic> gene was synthetized by a reverse transcriptase (TaKaRa) using primers 30, 31, and 32 (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>). After purification, cDNA was used as template for the 5&#x2032;RACE experiment in accordance with the manufacturer&#x2019;s recommendations (5&#x2032;RACE System for Rapid Amplification of cDNA Ends, Invitrogen), and using the TaKaRa Ex Taq<sup>TM</sup> DNA polymerase (TaKaRa Biotechnology). The purified PCR product was cloned in the pGEM<sup>&#x00AE;</sup>-T Easy vector (Promega) in <italic>E. coli</italic> DH5aaa and nine clones were sequenced.</p>
</sec>
<sec><title>&#x03B2;-Galactosidase Assays</title>
<p>Assays were performed with 0.5-ml aliquots of exponential-phase cultures (OD<sub>600</sub> = 0.6&#x2013;0.8) as described by <xref ref-type="bibr" rid="B25">Miller (1992)</xref> except that the incubation temperature was 37&#x00B0;C. Experiments were done at least five times for each strain. Treatment with mitomycin C was carried out as previously described (<xref ref-type="bibr" rid="B18">Guerin et al., 2009</xref>). One-way ANOVA statistical followed by <italic>post hoc</italic> Tukey HSD statistics tests were used to determine whether variation in expression levels were significant (<italic>p</italic>-values &#x003C; 0.01).</p>
</sec>
<sec><title>Electrophoresis Mobility Shift Assays (EMSA)</title>
<p>Over-expression and purification of the LexA protein was performed as previously described (<xref ref-type="bibr" rid="B11">Da Re et al., 2009</xref>). The EMSA probes were obtained by PCR using oligonucleotides 8 and 9 (probe PintI1, 270bp, Supplementary Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>) or 10 and 11 (probe PintI2, 233bp, Supplementary Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>) amplified from pAT674 or genomic DNA of isolate Dak 0898/12-14, respectively. They were end-labeled with [&#x03B3;<sup>32</sup>P]ATP (Amersham, Saclay, France) using T4 DNA polynucleotide kinase (Promega, Charbonni&#x00E8;res, France). The EMSA experiments were performed as previously described (<xref ref-type="bibr" rid="B11">Da Re et al., 2009</xref>) using various amounts of purified LexA, 40 ng of the radiolabelled DNA probe PintI1 or PintI2 in the binding mixtures, and 630 ng of unlabelled probe for competition experiments (around 15.75-fold excess).</p>
</sec>
</sec>
<sec><title>Results</title>
<sec><title>Mapping of the P<italic>intI2</italic> Promoter</title>
<p>To precisely identify the P<italic>intI2</italic> promoter, we used the 5&#x2032;RACE technique (<xref ref-type="bibr" rid="B15">Frohman, 1993</xref>). The P<italic>intI2</italic> transcription start site (TSS) was mapped at position -33 upstream from the IntI2 START codon, in agreement with previously inferred potential -35 and -10 elements (respectively, CAGGCA and TAGAAT, separated by 17 bp; GenBank accession number <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="L10818">L10818</ext-link>; <bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>). Downstream of P<italic>intI2</italic> lies a well-conserved putative translation initiation region (TIR; AAGGA-N7-ATG, see <bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>) compared to the bacterial TIR consensus sequence in <italic>E. coli</italic> (TAAGGA-N5/7-ATG) (<xref ref-type="bibr" rid="B22">Kozak, 2005</xref>). To experimentally validate P<italic>intI2</italic>, we tested its ability to drive the expression of the <italic>lacZ</italic> reporter gene by measuring &#x03B2;-galactosidase activity from two transcriptional fusions expressed in <italic>E. coli</italic> strain MG1656 and carried on plasmids pPintI2-1 and pPintI2-2 (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). Plasmid pPintI2-1 includes the whole <italic>attI2</italic> region fused to <italic>lacZ</italic>, while pPintI2-2 is restricted to the region corresponding to the putative P<italic>intI2</italic> promoter (<bold>Figure <xref ref-type="fig" rid="F2">2A</xref></bold>). Both constructs include the native TIR of <italic>intI2</italic>. We found similar levels of &#x03B2;-galactosidase activity with pPintI2-1 and pPintI2-2 (<bold>Figure <xref ref-type="fig" rid="F2">2B</xref></bold>). This activity was abolished by mutation of the most highly conserved bases of the PintI2-10 element, with respect to the &#x03C3;<sup>70</sup> promoter consensus (pPintI2-3; <bold>Table <xref ref-type="table" rid="T1">1</xref></bold> and <bold>Figures <xref ref-type="fig" rid="F2">2A,B</xref></bold>). These results confirmed the presence of a single functional P<italic>intI2</italic> promoter, CAGGCA-N17-TAGAAT.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p>Characterization and regulation of the P<italic>intI2</italic> promoter. <bold>(A)</bold> Schematic representation of the class 2 integron carried on Tn<italic>7</italic> and PintI2-<italic>lacZ</italic> translational fusions with the entire <italic>attI2</italic> site or P<italic>intI2</italic> promoter only carried on plasmids pPintI2-1, pPintI2-2, and pPintI2-3 (pPintI2-3 carrying an inactive PintI2). Boundaries of the cloned fragment are indicated by black dots and numbered according to the <italic>attI2</italic> region as shown in <bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>. The broken arrow represents the putative PintI2 promoter. The boundaries of the <italic>attI2</italic> region (nt4-nt314) are marked by vertical dotted lines. The inactivating mutation of the -10 sequence of PintI2 is indicated by a cross. <bold>(B)</bold> The strength of the P<italic>intI2</italic> promoter was measured in &#x03B2;-galactosidase assays with various P<italic>intI2</italic>-<italic>lacZ</italic> translational fusions in the wild-type strain MG1656 and in its &#x0394;<italic>lexA</italic> and &#x0394;<italic>recA</italic> derivatives. MMC: One-hour incubation with 1.6 mg/mL mitomycin C. At least five independent assays were performed for each plasmid. Error bars indicate standard deviation. Student&#x2019;s <italic>t</italic>-test was used for comparisons with MG1656/pPintI2-1: <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01; NS <italic>p</italic> > 0.05. <bold>(C)</bold> Electrophoresis mobility shift assay with the native P<italic>intI1</italic> and P<italic>intI2</italic> promoters, in the presence or absence of purified LexA protein (amounts are indicated in nanograms). The + sign indicates competition experiments performed with an excess of cold PintI1 or PintI2 as indicated on the side of the graph. F, free DNA; R, specific retarded complex.</p></caption>
<graphic xlink:href="fmicb-08-01499-g002.tif"/>
</fig>
</sec>
<sec><title>Expression of <italic>intI2</italic> Is Not Controlled by the SOS Response</title>
<p>Expression of the <italic>intI</italic> gene from P<italic>intI</italic> promoters in class 1 and <italic>V. cholerae</italic> chromosomal integrons is controlled by the LexA-mediated SOS response (<xref ref-type="bibr" rid="B18">Guerin et al., 2009</xref>). In class 2 integrons, a potential LexA binding site overlaps with the P<italic>intI2</italic> promoter (<bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>). To determine whether LexA regulates the expression of <italic>intI2</italic>, we measured &#x03B2;-galactosidase activity from pPintI2-1 in a <italic>lexA</italic>-deleted MG1656 derivative (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). Surprisingly, <italic>lexA</italic> deletion had no significant effect on &#x03B2;-galactosidase activity, nor did <italic>recA</italic> deletion or treatment with mitomycin C (induction of the SOS response) (<bold>Figure <xref ref-type="fig" rid="F2">2C</xref></bold>).</p>
<p>We performed EMSA with purified LexA protein and a PCR product encompassing P<italic>intI2</italic>. We showed that, unlike the promoter of class 1 integron integrase P<italic>intI1</italic> (<xref ref-type="bibr" rid="B18">Guerin et al., 2009</xref>), there was no specific gel shift with P<italic>intI2</italic>, meaning that LexA did not bind the putative LexA-binding site identified in the <italic>attI2</italic> region (<bold>Figure <xref ref-type="fig" rid="F2">2C</xref></bold>).</p>
<p>Together, these results strongly indicate that, despite the presence of a good canonical binding site for LexA protein within P<italic>intI2</italic>, this protein does not repress <italic>intI2</italic> transcription, and the SOS response does not control <italic>intI2</italic> expression.</p>
</sec>
<sec><title>Several Active Pc Promoters in the <italic>attI2</italic> Region</title>
<p>Four potential Pc2 promoters have previously been inferred (named here Pc2A to Pc2D), all located within the <italic>attI2</italic> region. We noticed the presence of another potential promoter located within the <italic>intI2</italic> encoding sequence (here named Pc2E), that displays a TGN-10 motif known to increase the strength of promoters (<xref ref-type="bibr" rid="B26">Mitchell et al., 2003</xref>) (TGGCTA-N13TGN-TAAGCT, 165-bp away from <italic>intI2</italic> START codon; <bold>Figure <xref ref-type="fig" rid="F3">3A</xref></bold>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p>Activity of putative class 2 integron Pc promoters. <bold>(A)</bold> Schematic representation of the class 2 integron carried on Tn<italic>7</italic> and Pc-<italic>lacZ</italic> translational fusions with the entire or partially deleted <italic>attI2</italic> site carried on plasmids pPc2-1&#x2013;pPc2-6. Boundaries of the cloned fragment are indicated by black dots and numbered according to its position in the pPc2-1 fragment (417 bp long). The cloned portion of the <italic>dfrA1</italic> coding sequence is indicated by a rectangle. Broken arrows represent each putative Pc2 promoter. The boundaries of the <italic>attI2</italic> region (nt4-nt314) are marked by vertical dotted lines. <bold>(B)</bold> The contribution of each putative Pc2 promoter (Pc2A&#x2013;Pc2E) was estimated by measuring &#x03B2;-galactosidase activity from each plasmid. pSU38&#x0394;tot<italic>lacZ</italic> is the empty control plasmid. At least five independent assays were performed for each construct. Error bars indicate the standard deviation. <italic>P</italic>-values (ANOVA and HSD Tukey&#x2019;s test) for comparison with pPc2-1 (on the top) and between constructs are indicated: <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01, NS <italic>p</italic> > 0.05.</p></caption>
<graphic xlink:href="fmicb-08-01499-g003.tif"/>
</fig>
<p>We studied the ability of these candidate Pc promoters to drive expression of the <italic>lacZ</italic> reporter gene, by successively deleting the putative promoters (pPc2-1 to pPc2-6; <bold>Figure <xref ref-type="fig" rid="F3">3A</xref></bold> and <bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). The strong activity measured from pPc2-1 (entire <italic>attI2</italic> region) argued for the presence of at least one functional promoter in <italic>attI2</italic> (<bold>Figure <xref ref-type="fig" rid="F3">3B</xref></bold>). When we added Pc2E (pPc2-2) or deleted Pc2D (pPc2-3), &#x03B2;-galactosidase activity was similar to that obtained with pPc2-1, showing that neither Pc2D nor Pc2E significantly contributes to gene cassette transcription in class 2 integrons (<bold>Figure <xref ref-type="fig" rid="F3">3B</xref></bold>). We assumed that the copy number was stable regardless the nature of the cloned fragment. Nevertheless, we cannot exclude that the small differences of promoter strength observed with Pc2-1, Pc2-2, and Pc2-3 could be explained by small variations of copy number. Nevertheless, these small differences of &#x03B2;-galactosidase activities were non-significant (<italic>p</italic> > 0.05, <bold>Figure <xref ref-type="fig" rid="F3">3B</xref></bold>).</p>
<p>On the contrary, deletion of Pc2A (pPc2-4) reduced &#x03B2;-galactosidase activity by 80%, and concomitant deletion of Pc2B (pPc2-5) halved the remaining activity, leaving a residual activity of less than 10%, which could be attributed to Pc2C (<bold>Figure <xref ref-type="fig" rid="F3">3B</xref></bold>). As expected, when none of the Pc2 promoters remained in the construct (pPc2-6), no &#x03B2;-galactosidase activity was detected (<bold>Figure <xref ref-type="fig" rid="F3">3B</xref></bold>).</p>
<p>These results suggested that three of the four potential promoters located in the <italic>attI2</italic> region, namely Pc2A, Pc2B, and Pc2C, may contribute to gene cassette expression, and that Pc2A would be the major actor.</p>
</sec>
<sec><title>Promoters Pc2A and Pc2B Contribute to Gene Cassette Expression</title>
<p>The coexistence of three potentially active Pc2 promoters (Pc2A&#x2013;Pc2C) raised the question of their respective contributions to gene cassette expression. To address this question, we inactivated them individually or concomitantly in pPc2-1 (pPc2-7 to pPc2-10; <bold>Figure <xref ref-type="fig" rid="F4">4A</xref></bold>), by placing mutations at key positions in their respective putative -10 elements (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). As shown in <bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>, inactivation of Pc2C in pPc2-1 (pPc2-10) had no significant effect on &#x03B2;-galactosidase expression, though Pc2C inactivation in pPc2-5 abolished all activity (<bold>Figure <xref ref-type="fig" rid="F4">4C</xref></bold>). In contrast, inactivation of Pc2A (pPc2-7) or Pc2B (pPc2-8) reduced the overall expression level by 53 and 32%, respectively (<bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>). Surprisingly, when both Pc2A and Pc2B (pPc2-9) were mutated, 25% of the initial pPc2-1 &#x03B2;-galactosidase activity remained (<bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>). Indeed, as Pc2C did not appear to contribute to the activity from pPc2-1, we expected that double mutation of Pc2A and Pc2B would lead to a complete loss of activity. However, as mutation of Pc2A reduced pPc2-1 activity by around 50%, a similar decrease should have been observed after Pc2B mutation, which was not the case (<bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>). We thus verified whether the mutation introduced in the putative -10 element of Pc2A and Pc2B (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>) resulted in complete abolition of promoter activity. We cloned the wildtype and mutated Pc2A and Pc2B promoter regions in fusion with <italic>lacZ</italic> (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>), and found that although the mutation in Pc2A abolished completely the promoter activity, the activity of mutated Pc2B (pPc2B<sup>&#x2217;</sup>) was reduced by only 60% compared to wildtype Pc2B (pPc2B) (<bold>Figure <xref ref-type="fig" rid="F4">4C</xref></bold>), suggesting that its -10 sequence might differ slightly from that previously inferred (Genbank accession number <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="AM261760">AM261760</ext-link>). These results indicate that Pc2A and Pc2B contribute equally to gene cassette expression in class 2 integrons.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p>Specific contributions of the Pc2A, Pc2B and Pc2C promoters. <bold>(A)</bold> Schematic representation of the class 2 integron carried on Tn<italic>7</italic>, Pc-<italic>lacZ</italic> translational fusions with the entire or partially deleted <italic>attI2</italic> site carrying functional or mutated Pc promoters carried on pPc2-1, pPc2-7 to pPc2-10 and pPc2-5 and pPc2-5<sup>&#x2217;</sup>; and Pc-<italic>lacZ</italic> transcriptional fusions with WT or mutated Pc2A and Pc2B carried on plasmids pPc2A, pPc2A<sup>&#x2217;</sup>, pPc2B and pPc2B<sup>&#x2217;</sup>, respectively. Inactivating mutation of a promoter -10 sequence is indicated by a cross. The wild type and mutated -10 sequences are written under the promoters with mutated residues shown in lowercases. Boundaries of the cloned fragment are indicated by black dots and numbered as in <bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>. The cloned portion of the <italic>dfrA1</italic> coding sequence is indicated by a rectangle. Broken arrows represent each Pc2 promoter, and their coordinates (1st base of its -35 element and last base of its -10 element) are indicated for individually cloned promoters. <bold>(B)</bold> The contribution of promoters Pc2A, Pc2B and Pc2C within <italic>attI2</italic> was estimated by measuring &#x03B2;-galactosidase activity from constructs carrying one or several inactivated promoters. <bold>(C)</bold> Individual promoter strength was estimated by measuring &#x03B2;-galactosidase activity. At least five independent assays were performed for each construct. Error bars indicate the standard deviation. <italic>P</italic>-values (ANOVA and HSD Tukey&#x2019;s test) for comparisons with pPc2-1 <bold>(B)</bold> or with the respective WT promoter <bold>(C)</bold> are indicated: <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01, NS <italic>p</italic> > 0.05.</p></caption>
<graphic xlink:href="fmicb-08-01499-g004.tif"/>
</fig>
</sec>
<sec><title>Polymorphism of Class 2 Pc Promoters</title>
<p>There are several variants of the Pc promoter from class 1 and 3 integrons (<xref ref-type="bibr" rid="B8">Collis et al., 2002</xref>; <xref ref-type="bibr" rid="B21">Jov&#x00E9; et al., 2010</xref>). We performed an <italic>in silico</italic> analysis of all class 2 integron sequences available online (May 2016), and found that six of the 220 analyzed sequences exhibited variations in Pc2A and Pc2B (accession numbers: <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="DQ533990">DQ533990</ext-link>, <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="DQ533991">DQ533991</ext-link>, <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="EU780012">EU780012</ext-link>, <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="CP012363">CP012363</ext-link>, <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="CP012365">CP012365</ext-link>, and <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="KU736868">KU736868</ext-link>). These six class 2 integrons all contain an A to G substitution converting the -10 element of Pc2A into TAAA<underline>G</underline>T, and a G to A substitution converting the -35 element of Pc2B into TT<underline>A</underline>TAT. Hereafter, we will call these promoters Pc2A-V2 and Pc2B-V2, respectively. In one of these integrons, DQ533990, the -35 element of Pc2B-V2 is also duplicated.</p>
<p>To investigate the impact of this Pc2 polymorphism on the strength of promoters Pc2A/Pc2B, we introduced the Pc2A-V2 and/or Pc2B-V2 mutations in the pPc2-1 plasmid (<bold>Figure <xref ref-type="fig" rid="F5">5A</xref></bold>). Replacing Pc2A by Pc2A-V2 or Pc2B by Pc2B-V2 significantly reduced <italic>lacZ</italic> expression by 39 and 12%, respectively (<bold>Figure <xref ref-type="fig" rid="F5">5B</xref></bold>). When both promoters Pc2A and Pc2B were replaced by their variants Pc2A-V2 and Pc2B-V2, there was an additive effect, and &#x03B2;-galactosidase expression fell by 57% compared to that obtained with pPc2-1 (<bold>Figure <xref ref-type="fig" rid="F5">5</xref></bold>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p>Strength of the Pc2A and Pc2B promoter variants. <bold>(A)</bold> Schematic representation of Pc-<italic>lacZ</italic> translational fusions with the entire <italic>attI2</italic> sites carrying combinations of promoters Pc2A, Pc2B, Pc2A-v2 and Pc2B-v2. Sequences of the -10 or -35 elements of, respectively, Pc2A and Pc2B promoters are written. Boundaries of the cloned fragment are indicated by black dots. The cloned portion of the <italic>dfrA1</italic> coding sequence is indicated by a rectangle. Broken arrows represent the Pc promoters. <bold>(B)</bold> The contribution of the Pc2A and Pc2B variants to gene cassette expression was estimated by measuring &#x03B2;-galactosidase activity from the various constructs. At least five independent assays were performed for each construct. Error bars indicate the standard deviation. <italic>P</italic>-values (ANOVA and HSD Tukey&#x2019;s test) for the comparison with pPc2-1 are indicated: <sup>&#x2217;</sup><italic>p</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01.</p></caption>
<graphic xlink:href="fmicb-08-01499-g005.tif"/>
</fig>
<p>Interestingly, the Pc2A-V2 and Pc2B-V2 variants were always found associated only in class 2 integrons encoding a complete integrase gene, with no premature STOP codon, that has been shown to encode a functional IntI2 protein (<xref ref-type="bibr" rid="B20">Hansson et al., 2002</xref>). None of these variants could be recovered in class 2 integrons encoding a truncated integrase.</p>
</sec>
</sec>
<sec><title>Discussion</title>
<p>This work highlights particularities in the expression of the integrase and gene cassettes of class 2 integrons. After mapping the P<italic>intI2</italic> promoter (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>), we showed that despite the presence of a potential LexA box, LexA did not bind this region. Thus, integrase expression is not regulated by the SOS response in class 2 integrons, contrary to what has been shown for class 1 and <italic>V. cholerae</italic> integrons (<xref ref-type="bibr" rid="B18">Guerin et al., 2009</xref>). Interestingly, <xref ref-type="bibr" rid="B6">Cambray et al. (2011)</xref> found a correlation between the lack of a LexA binding box and an inactive integrase. In their analysis, four classes of integron, including class 2, did not fit this general scheme, as they displayed both a putative LexA operator and an inactive integrase (<xref ref-type="bibr" rid="B6">Cambray et al., 2011</xref>). As we show here that <italic>intI2</italic> expression is not SOS-dependent, class 2 integrons also comply with this general model, belonging to integron classes in which the absence of LexA control correlates with an inactive integrase. Closer examination of the class 2 integron putative LexA operator (<underline>CTG</underline>TATAGGCAGA<underline>CAG</underline>) revealed the presence of 4 C/Gs, with a stretch of 3 consecutive C/Gs, in the 10-bp central variable region, whereas most experimentally validated LexA operators in <italic>E. coli</italic> display only 3 or fewer C/Gs in this region<sup><xref ref-type="fn" rid="fn01">1</xref></sup>. One can hypothesize that the lack of the usual TA stretch within the class 2 integron putative LexA site may explain why LexA does not bind this site. In the three other integron classes with both a putative LexA operator and an inactive integrase, the putative LexA operator includes 0 or 1 C/G in the central region (<xref ref-type="bibr" rid="B6">Cambray et al., 2011</xref>). In class 1 integrons, besides LexA-dependent regulation, expression of the integrase gene is also inhibited by transcriptional interference from the strong Pc variant, due to the face-to-face arrangement of the Pc and P<italic>intI1</italic> promoters (<xref ref-type="bibr" rid="B18">Guerin et al., 2009</xref>). In class 2 integrons, the Pc promoters (Pc2A and Pc2B) and P<italic>intI2</italic> are arranged tail-to-tail, so no such transcriptional interference can exist and <italic>intI2</italic> should be constitutively expressed. Consistently, we found no significant difference in &#x03B2;-galactosidase activity with pPintI2-2 (P<italic>intI2</italic> cloned alone) and pPintI2-1 (entire <italic>attI2</italic> site, includes the Pc2 promoters) (<bold>Figure <xref ref-type="fig" rid="F2">2</xref></bold>). Although <italic>intI2</italic> is fully expressed, the encoded integrase is not functional, owing to the ochre codon in position 179. <xref ref-type="bibr" rid="B20">Hansson et al. (2002)</xref> suggested that this shortened 178-aa IntI2 peptide might interfere with the <italic>attI2</italic> site, preventing any IntI-mediated recombination. This hypothesis could explain the stability of the gene cassette array of class 2 integrons (<xref ref-type="bibr" rid="B20">Hansson et al., 2002</xref>). Consistently, the rare class 2 integrons that encode an active IntI2 integrase display a broader range of gene cassettes and gene cassette arrays (Supplementary Figure <xref ref-type="supplementary-material" rid="SM2">S1</xref>).</p>
<p>This work also highlights two specificities of gene cassette expression in class 2 integrons: (i) the Pc2 promoter is located in the <italic>attI</italic> region and not within the <italic>intI</italic> gene as in other integrons (<xref ref-type="bibr" rid="B7">Collis and Hall, 1995</xref>; <xref ref-type="bibr" rid="B8">Collis et al., 2002</xref>; <xref ref-type="bibr" rid="B2">Baharoglu et al., 2012</xref>), and (ii) at least two promoters, Pc2A and Pc2B, are involved in gene cassette expression. Although we observed weak activity of the putative Pc2C promoter when Pc2A and Pc2B were removed (<bold>Figure <xref ref-type="fig" rid="F3">3B</xref></bold>), Pc2C inactivation within the entire <italic>attI2</italic> region had no effect on &#x03B2;-galactosidase activity (<bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>). This indicated that the contribution of Pc2C to gene cassette expression is negligible which is consistent with its structure, since it displays a suboptimal 19-bp long spacer between the -35 and -10 elements (<xref ref-type="bibr" rid="B26">Mitchell et al., 2003</xref>).</p>
<p>The permanent coexistence of two functional Pc promoters within the integron <italic>attI</italic> region is a unique feature of class 2 integrons. In class 1 integrons, two gene cassette promoters namely Pc and the P2 have been also described but in only 10% of the integrons (<xref ref-type="bibr" rid="B7">Collis and Hall, 1995</xref>; <xref ref-type="bibr" rid="B21">Jov&#x00E9; et al., 2010</xref>). The biological reason for the presence of two active Pc promoters in class 2 integrons is unclear. Further studies are needed to determine whether the presence of these two functional gene cassette promoters in class 2 integrons might be linked to differential regulation of these promoters. One can hypothesize that this peculiar organization might be linked to specific activation of Pc2A and/or Pc2B, either under specific conditions, e.g., in response to distinct lifestyle conditions, or by specific partner proteins.</p>
<p>As in class 1 and 3 integrons (<xref ref-type="bibr" rid="B7">Collis and Hall, 1995</xref>; <xref ref-type="bibr" rid="B9">Correia et al., 2003</xref>; <xref ref-type="bibr" rid="B21">Jov&#x00E9; et al., 2010</xref>), there are several Pc variants of different strengths in class 2 integrons. We show here that the class 2 integron promoters Pc2A-V2 and Pc2B-V2 variants are less efficient than Pc2A and Pc2B for gene cassette expression (<bold>Figure <xref ref-type="fig" rid="F5">5</xref></bold>). Interestingly, the Pc2A-V2 and Pc2B-V2 variants have so far always been found together, in association with class 2 integrons that encode a functional IntI2 integrase (<xref ref-type="bibr" rid="B3">Barlow and Gobius, 2006</xref>; <xref ref-type="bibr" rid="B24">M&#x00E1;rquez et al., 2008</xref>; <xref ref-type="bibr" rid="B31">Rodr&#x00ED;guez-Minguela et al., 2009</xref>; <xref ref-type="bibr" rid="B35">Wei et al., 2014</xref>). This observed inverse correlation between the level of gene cassette expression and integrase activity raises another analogy with the class 1 integron model in which the weaker the Pc variant, the more efficient the IntI1 integrase (<xref ref-type="bibr" rid="B21">Jov&#x00E9; et al., 2010</xref>).</p>
<p>Taken together, our data reveal the existence of two categories of class 2 integrons. The most prevalent category efficiently expresses a limited pool of gene cassettes from promoters Pc2A and Pc2B but is unable to modify its gene cassette array (non-functional IntI2). The rarer category produces an active integrase that permits gene cassette acquisition/rearrangement but expresses the gene cassettes more weakly (twofold; <bold>Figure <xref ref-type="fig" rid="F5">5</xref></bold>). The rarity of functional class 2 integrons may be due to a high fitness cost associated with constitutive <italic>intI2</italic> expression. Indeed, even though constitutive <italic>intI2</italic> expression might represent an advantage because integrase production is not conditional on an environmental stimulus, it can also be a drawback, given the potential biological cost of <italic>intI2</italic> expression or activity. Indeed, it is known than in <italic>Acinetobacter</italic> and in <italic>E. coli</italic>, expression of the class 1 integron integrase gene is deleterious, with a high fitness cost, and this can lead to inactivation of the integrase (<xref ref-type="bibr" rid="B33">Starikova et al., 2012</xref>; <xref ref-type="bibr" rid="B23">Lacotte et al., 2017</xref>).</p>
<p>We propose an evolutionary model for class 2 integrons in which the expression of the ancestral class 2 integrons integrase was under control of the SOS response (<bold>Figure <xref ref-type="fig" rid="F6">6A</xref></bold>). Then, mutation in the LexA operator would have led to a constitutive expression of the integrase gene encoding a fully active IntI2 (<bold>Figure <xref ref-type="fig" rid="F6">6B</xref></bold>). The resulting high fitness cost would have lead to the introduction of either (i) a nonsense mutation in the <italic>intI2</italic> gene that inactivated IntI2 but maintained an array of highly expressed gene cassettes; this would have given rise to the currently prevailing class 2 integrons (<bold>Figure <xref ref-type="fig" rid="F6">6C</xref></bold>), or (ii) mutations within the Pc promoters, generating variants of weaker activity, in order to reduce gene cassette expression and the potentially associated fitness cost (<bold>Figure <xref ref-type="fig" rid="F6">6D</xref></bold>). This latter group of class 2 integrons constitutively express a functional IntI2 whose high fitness cost may explain their rarity.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption><p>Model of evolution of <italic>intI</italic> and Pc promoters in class 2 integrons. <bold>(A)</bold> Ancestral class 2 integron. The <italic>intI2</italic> gene encodes a functional IntI2 integrase. LexA binds its operator and represses the expression of <italic>intI2</italic>. The Pc2 promoters are the V1 versions (high level of cassette gene expression). <bold>(B)</bold> Evolution of the LexA operator preventing LexA binding leading to derepression of <italic>intI2</italic> expression. Constitutive expression of <italic>intI2</italic> increases the fitness cost of the class 2 integron. This higher fitness cost is counterbalanced through mutations <bold>(C)</bold>, introducing of a premature STOP codon in the IntI2 coding sequence, releasing the fitness cost, and giving raise to the prevailing current class 2 integrons; <bold>(D)</bold> weakening the Pc2 promoters (Pc2AV2 and Pc2BV2) but keeping an active integrase, this evolution pathway being rare.</p></caption>
<graphic xlink:href="fmicb-08-01499-g006.tif"/>
</fig>
</sec>
<sec><title>Author Contributions</title>
<p>M-CP and TJ conceived the study. M-CP coordinated the study. TJ, AT, and SDR performed the experiments. TJ, M-CP, and SDR analyzed the data and wrote the manuscript. AG-S revised the manuscript.</p>
</sec>
<sec><title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported by grants from Minist&#x00E8;re de l&#x2019;Enseignement Sup&#x00E9;rieur et de la Recherche, Conseil R&#x00E9;gional du Limousin, Institut National de la Sant&#x00E9; et de la Recherche M&#x00E9;dicale (Inserm), and Fondation pour la Recherche M&#x00E9;dicale (FRM DEQ20150331742 to M-CP). TJ is a post-doctoral Inserm fellow. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</p>
</fn>
</fn-group>
<ack>
<p>The authors thank the members of the lab for fruitful discussions.</p>
</ack>
<sec sec-type="supplementary material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="http://journal.frontiersin.org/article/10.3389/fmicb.2017.01499/full#supplementary-material">http://journal.frontiersin.org/article/10.3389/fmicb.2017.01499/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.PDF" id="SM1" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image_1.tiff" id="SM2" mimetype="image/tif" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname> <given-names>A. M.</given-names></name> <name><surname>Nakano</surname> <given-names>H.</given-names></name> <name><surname>Shimamoto</surname> <given-names>T.</given-names></name></person-group> (<year>2005</year>). <article-title>Molecular characterization of integrons in non-typhoid <italic>Salmonella</italic> serovars isolated in Japan: description of an unusual class 2 integron.</article-title> <source><italic>J. Antimicrob. Chemother.</italic></source> <volume>55</volume> <fpage>371</fpage>&#x2013;<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkh534</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baharoglu</surname> <given-names>Z.</given-names></name> <name><surname>Krin</surname> <given-names>E.</given-names></name> <name><surname>Mazel</surname> <given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Connecting environment and genome plasticity in the characterization of transformation-induced SOS regulation and carbon catabolite control of the <italic>Vibrio cholerae</italic> integron integrase.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>194</volume> <fpage>1659</fpage>&#x2013;<lpage>1667</lpage>. <pub-id pub-id-type="doi">10.1128/JB.05982-11</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barlow</surname> <given-names>R. S.</given-names></name> <name><surname>Gobius</surname> <given-names>K. S.</given-names></name></person-group> (<year>2006</year>). <article-title>Diverse class 2 integrons in bacteria from beef cattle sources.</article-title> <source><italic>J. Antimicrob. Chemother.</italic></source> <volume>58</volume> <fpage>1133</fpage>&#x2013;<lpage>1138</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkl423</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biskri</surname> <given-names>L.</given-names></name> <name><surname>Mazel</surname> <given-names>D.</given-names></name></person-group> (<year>2003</year>). <article-title>Erythromycin esterase gene <italic>ere(A)</italic> is located in a functional gene cassette in an unusual class 2 integron.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>47</volume> <fpage>3326</fpage>&#x2013;<lpage>3331</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.47.10.3326-3331.2003</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cambray</surname> <given-names>G.</given-names></name> <name><surname>Guerout</surname> <given-names>A.-M.</given-names></name> <name><surname>Mazel</surname> <given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>Integrons.</article-title> <source><italic>Annu. Rev. Genet.</italic></source> <volume>44</volume> <fpage>141</fpage>&#x2013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-genet-102209-163504</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cambray</surname> <given-names>G.</given-names></name> <name><surname>Sanchez-Alberola</surname> <given-names>N.</given-names></name> <name><surname>Campoy</surname> <given-names>S.</given-names></name> <name><surname>Guerin</surname> <given-names>E.</given-names></name> <name><surname>Da Re</surname> <given-names>S.</given-names></name> <name><surname>Gonz&#x00E1;lez-Zorn</surname> <given-names>B.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Prevalence of SOS-mediated control of integron integrase expression as an adaptive trait of chromosomal and mobile integrons.</article-title> <source><italic>Mob. DNA</italic></source> <volume>2</volume>:<issue>6</issue>. <pub-id pub-id-type="doi">10.1186/1759-8753-2-6</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collis</surname> <given-names>C. M.</given-names></name> <name><surname>Hall</surname> <given-names>R. M.</given-names></name></person-group> (<year>1995</year>). <article-title>Expression of antibiotic resistance genes in the integrated cassettes of integrons.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>39</volume> <fpage>155</fpage>&#x2013;<lpage>162</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.39.1.155</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collis</surname> <given-names>C. M.</given-names></name> <name><surname>Kim</surname> <given-names>M.-J.</given-names></name> <name><surname>Partridge</surname> <given-names>S. R.</given-names></name> <name><surname>Stokes</surname> <given-names>H. W.</given-names></name> <name><surname>Hall</surname> <given-names>R. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Characterization of the class 3 integron and the site-specific recombination system it determines.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>184</volume> <fpage>3017</fpage>&#x2013;<lpage>3026</lpage>. <pub-id pub-id-type="doi">10.1128/JB.184.11.3017-3026.2002</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Correia</surname> <given-names>M.</given-names></name> <name><surname>Boavida</surname> <given-names>F.</given-names></name> <name><surname>Grosso</surname> <given-names>F.</given-names></name> <name><surname>Salgado</surname> <given-names>M. J.</given-names></name> <name><surname>Lito</surname> <given-names>L. M.</given-names></name> <name><surname>Cristino</surname> <given-names>J. M.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Molecular characterization of a new class 3 integron in <italic>Klebsiella pneumoniae</italic>.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>47</volume> <fpage>2838</fpage>&#x2013;<lpage>2843</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.47.9.2838-2843.2003</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>da Fonseca</surname> <given-names>&#x00C9;. L.</given-names></name> <name><surname>dos Santos Freitas</surname> <given-names>F.</given-names></name> <name><surname>Vicente</surname> <given-names>A. C. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Pc promoter from class 2 integrons and the cassette transcription pattern it evokes.</article-title> <source><italic>J. Antimicrob. Chemother.</italic></source> <volume>66</volume> <fpage>797</fpage>&#x2013;<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkr011</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Da Re</surname> <given-names>S.</given-names></name> <name><surname>Garnier</surname> <given-names>F.</given-names></name> <name><surname>Gu&#x00E9;rin</surname> <given-names>E.</given-names></name> <name><surname>Campoy</surname> <given-names>S.</given-names></name> <name><surname>Denis</surname> <given-names>F.</given-names></name> <name><surname>Ploy</surname> <given-names>M.-C.</given-names></name></person-group> (<year>2009</year>). <article-title>The SOS response promotes qnrB quinolone-resistance determinant expression.</article-title> <source><italic>EMBO Rep.</italic></source> <volume>10</volume> <fpage>929</fpage>&#x2013;<lpage>933</lpage>. <pub-id pub-id-type="doi">10.1038/embor.2009.99</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname> <given-names>V.</given-names></name> <name><surname>Parizano</surname> <given-names>M.-P.</given-names></name> <name><surname>Arpin</surname> <given-names>C.</given-names></name> <name><surname>Coulange</surname> <given-names>L.</given-names></name> <name><surname>Bezian</surname> <given-names>M.-C.</given-names></name> <name><surname>Quentin</surname> <given-names>C.</given-names></name></person-group> (<year>2007</year>). <article-title>High genetic stability of integrons in clinical isolates of <italic>Shigella</italic> spp. of worldwide origin.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>51</volume> <fpage>1333</fpage>&#x2013;<lpage>1340</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01109-06</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Escudero</surname> <given-names>J. A.</given-names></name> <name><surname>Loot</surname> <given-names>C.</given-names></name> <name><surname>Nivina</surname> <given-names>A.</given-names></name> <name><surname>Mazel</surname> <given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>The Integron: adaptation on demand.</article-title> <source><italic>Microbiol. Spectr.</italic></source> <volume>3</volume> MDN<fpage>A3</fpage>&#x2013;<lpage>0019</lpage>&#x2013;2014. <pub-id pub-id-type="doi">10.1128/microbiolspec.MDNA3-0019-2014</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esp&#x00E9;li</surname> <given-names>O.</given-names></name> <name><surname>Moulin</surname> <given-names>L.</given-names></name> <name><surname>Boccard</surname> <given-names>F.</given-names></name></person-group> (<year>2001</year>). <article-title>Transcription attenuation associated with bacterial repetitive extragenic BIME elements.</article-title> <source><italic>J. Mol. Biol.</italic></source> <volume>314</volume> <fpage>375</fpage>&#x2013;<lpage>386</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.2001.5150</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frohman</surname> <given-names>M. A.</given-names></name></person-group> (<year>1993</year>). <article-title>Rapid amplification of complementary DNA ends for generation of full-length complementary DNAs: thermal RACE.</article-title> <source><italic>Methods Enzymol.</italic></source> <volume>218</volume> <fpage>340</fpage>&#x2013;<lpage>356</lpage>. <pub-id pub-id-type="doi">10.1016/0076-6879(93)18026-9</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gassama Sow</surname> <given-names>A.</given-names></name> <name><surname>Diallo</surname> <given-names>M. H.</given-names></name> <name><surname>Gatet</surname> <given-names>M.</given-names></name> <name><surname>Denis</surname> <given-names>F.</given-names></name> <name><surname>A&#x00EF;dara-Kane</surname> <given-names>A.</given-names></name> <name><surname>Ploy</surname> <given-names>M.-C.</given-names></name></person-group> (<year>2008</year>). <article-title>Description of an unusual class 2 integron in <italic>Shigella sonnei</italic> isolates in Senegal (sub-Saharan Africa).</article-title> <source><italic>J. Antimicrob. Chemother.</italic></source> <volume>62</volume> <fpage>843</fpage>&#x2013;<lpage>844</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkn264</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gillings</surname> <given-names>M. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Integrons: past, present, and future.</article-title> <source><italic>Microbiol. Mol. Biol. Rev. MMBR</italic></source> <volume>78</volume> <fpage>257</fpage>&#x2013;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1128/MMBR.00056-13</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guerin</surname> <given-names>E.</given-names></name> <name><surname>Cambray</surname> <given-names>G.</given-names></name> <name><surname>Sanchez-Alberola</surname> <given-names>N.</given-names></name> <name><surname>Campoy</surname> <given-names>S.</given-names></name> <name><surname>Erill</surname> <given-names>I.</given-names></name> <name><surname>Da Re</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>The SOS response controls integron recombination.</article-title> <source><italic>Science</italic></source> <volume>324</volume> <issue>1034</issue>. <pub-id pub-id-type="doi">10.1126/science.1172914</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname> <given-names>R. M.</given-names></name> <name><surname>Stokes</surname> <given-names>H. W.</given-names></name></person-group> (<year>1993</year>). <article-title>Integrons: novel DNA elements which capture genes by site-specific recombination.</article-title> <source><italic>Genetica</italic></source> <volume>90</volume> <fpage>115</fpage>&#x2013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1007/BF01435034</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname> <given-names>K.</given-names></name> <name><surname>Sundstr&#x00F6;m</surname> <given-names>L.</given-names></name> <name><surname>Pelletier</surname> <given-names>A.</given-names></name> <name><surname>Roy</surname> <given-names>P. H.</given-names></name></person-group> (<year>2002</year>). <article-title>IntI2 integron integrase in Tn<italic>7</italic>.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>184</volume> <fpage>1712</fpage>&#x2013;<lpage>1721</lpage>. <pub-id pub-id-type="doi">10.1128/JB.184.6.1712-1721.2002</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jov&#x00E9;</surname> <given-names>T.</given-names></name> <name><surname>Da Re</surname> <given-names>S.</given-names></name> <name><surname>Denis</surname> <given-names>F.</given-names></name> <name><surname>Mazel</surname> <given-names>D.</given-names></name> <name><surname>Ploy</surname> <given-names>M.-C.</given-names></name></person-group> (<year>2010</year>). <article-title>Inverse correlation between promoter strength and excision activity in class 1 integrons.</article-title> <source><italic>PLoS Genet.</italic></source> <volume>6</volume>:<issue>e1000793</issue>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1000793</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozak</surname> <given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>Regulation of translation via mRNA structure in prokaryotes and eukaryotes.</article-title> <source><italic>Gene</italic></source> <volume>361</volume> <fpage>13</fpage>&#x2013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2005.06.037</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacotte</surname> <given-names>Y.</given-names></name> <name><surname>Ploy</surname> <given-names>M.-C.</given-names></name> <name><surname>Raherison</surname> <given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Class 1 integrons are low-cost structures in <italic>Escherichia coli</italic>.</article-title> <source><italic>ISME J.</italic></source> <volume>11</volume> <fpage>1535</fpage>&#x2013;<lpage>1544</lpage>. <pub-id pub-id-type="doi">10.1038/ismej.2017.38</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x00E1;rquez</surname> <given-names>C.</given-names></name> <name><surname>Labbate</surname> <given-names>M.</given-names></name> <name><surname>Ingold</surname> <given-names>A. J.</given-names></name> <name><surname>Roy Chowdhury</surname> <given-names>P.</given-names></name> <name><surname>Ram&#x00ED;rez</surname> <given-names>M. S.</given-names></name> <name><surname>Centr&#x00F3;n</surname> <given-names>D.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Recovery of a functional class 2 integron from an <italic>Escherichia coli</italic> strain mediating a urinary tract infection.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>52</volume> <fpage>4153</fpage>&#x2013;<lpage>4154</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00710-08</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>J. H.</given-names></name></person-group> (<year>1992</year>). <source><italic>A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria</italic>.</source> <publisher-loc>Plainview, NY</publisher-loc>: <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>.</citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname> <given-names>J. E.</given-names></name> <name><surname>Zheng</surname> <given-names>D.</given-names></name> <name><surname>Busby</surname> <given-names>S. J. W.</given-names></name> <name><surname>Minchin</surname> <given-names>S. D.</given-names></name></person-group> (<year>2003</year>). <article-title>Identification and analysis of &#x201C;extended -10&#x201D; promoters in <italic>Escherichia coli</italic>.</article-title> <source><italic>Nucleic Acids Res.</italic></source> <volume>31</volume> <fpage>4689</fpage>&#x2013;<lpage>4695</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkg694</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moura</surname> <given-names>A.</given-names></name> <name><surname>Soares</surname> <given-names>M.</given-names></name> <name><surname>Pereira</surname> <given-names>C.</given-names></name> <name><surname>Leit&#x00E3;o</surname> <given-names>N.</given-names></name> <name><surname>Henriques</surname> <given-names>I.</given-names></name> <name><surname>Correia</surname> <given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>INTEGRALL: a database and search engine for integrons, integrases and gene cassettes.</article-title> <source><italic>Bioinforma. Oxf. Engl.</italic></source> <volume>25</volume> <fpage>1096</fpage>&#x2013;<lpage>1098</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp105</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ploy</surname> <given-names>M. C.</given-names></name> <name><surname>Courvalin</surname> <given-names>P.</given-names></name> <name><surname>Lambert</surname> <given-names>T.</given-names></name></person-group> (<year>1998</year>). <article-title>Characterization of In40 of <italic>Enterobacter</italic> aerogenes BM2688, a class 1 integron with two new gene cassettes, <italic>cmlA2</italic> and <italic>qacF</italic>.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>42</volume> <fpage>2557</fpage>&#x2013;<lpage>2563</lpage>.</citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ram&#x00ED;rez</surname> <given-names>M. S.</given-names></name> <name><surname>Pi&#x00F1;eiro</surname> <given-names>S.</given-names></name> <collab>Argentinian Integron Study Group</collab> <name><surname>Centr&#x00F3;n</surname> <given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>Novel insights about class 2 integrons from experimental and genomic epidemiology.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>54</volume> <fpage>699</fpage>&#x2013;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01392-08</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ram&#x00ED;rez</surname> <given-names>M. S.</given-names></name> <name><surname>Vargas</surname> <given-names>L. J.</given-names></name> <name><surname>Cagnoni</surname> <given-names>V.</given-names></name> <name><surname>Tokumoto</surname> <given-names>M.</given-names></name> <name><surname>Centr&#x00F3;n</surname> <given-names>D.</given-names></name></person-group> (<year>2005</year>). <article-title>Class 2 integron with a novel cassette array in a <italic>Burkholderia cenocepacia</italic> isolate.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>49</volume> <fpage>4418</fpage>&#x2013;<lpage>4420</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.49.10.4418-4420.2005</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x00ED;guez-Minguela</surname> <given-names>C. M.</given-names></name> <name><surname>Apajalahti</surname> <given-names>J. H. A.</given-names></name> <name><surname>Chai</surname> <given-names>B.</given-names></name> <name><surname>Cole</surname> <given-names>J. R.</given-names></name> <name><surname>Tiedje</surname> <given-names>J. M.</given-names></name></person-group> (<year>2009</year>). <article-title>Worldwide prevalence of class 2 integrases outside the clinical setting is associated with human impact.</article-title> <source><italic>Appl. Environ. Microbiol.</italic></source> <volume>75</volume> <fpage>5100</fpage>&#x2013;<lpage>5110</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.00133-09</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simonsen</surname> <given-names>C. C.</given-names></name> <name><surname>Chen</surname> <given-names>E. Y.</given-names></name> <name><surname>Levinson</surname> <given-names>A. D.</given-names></name></person-group> (<year>1983</year>). <article-title>Identification of the type I trimethoprim-resistant dihydrofolate reductase specified by the <italic>Escherichia coli</italic> R-plasmid R483: comparison with procaryotic and eucaryotic dihydrofolate reductases.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>155</volume> <fpage>1001</fpage>&#x2013;<lpage>1008</lpage>.</citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Starikova</surname> <given-names>I.</given-names></name> <name><surname>Harms</surname> <given-names>K.</given-names></name> <name><surname>Haugen</surname> <given-names>P.</given-names></name> <name><surname>Lunde</surname> <given-names>T. T. M.</given-names></name> <name><surname>Primicerio</surname> <given-names>R.</given-names></name> <name><surname>Samuelsen</surname> <given-names>&#x00D8;,</given-names></name></person-group><etal/> (<year>2012</year>). <article-title>A trade-off between the fitness cost of functional integrases and long-term stability of integrons.</article-title> <source><italic>PLoS Pathog.</italic></source> <volume>8</volume>:<issue>e1003043</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1003043</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname> <given-names>H. W.</given-names></name> <name><surname>Hall</surname> <given-names>R. M.</given-names></name></person-group> (<year>1989</year>). <article-title>A novel family of potentially mobile DNA elements encoding site-specific gene-integration functions: integrons.</article-title> <source><italic>Mol. Microbiol.</italic></source> <volume>3</volume> <fpage>1669</fpage>&#x2013;<lpage>1683</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2958.1989.tb00153.x</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>Q.</given-names></name> <name><surname>Hu</surname> <given-names>Q.</given-names></name> <name><surname>Li</surname> <given-names>S.</given-names></name> <name><surname>Lu</surname> <given-names>H.</given-names></name> <name><surname>Chen</surname> <given-names>G.</given-names></name> <name><surname>Shen</surname> <given-names>B.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>A novel functional class 2 integron in clinical <italic>Proteus mirabilis</italic> isolates.</article-title> <source><italic>J. Antimicrob. Chemother.</italic></source> <volume>69</volume> <fpage>973</fpage>&#x2013;<lpage>976</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkt456</pub-id></citation></ref>
</ref-list>
<fn-group>
<fn id="fn01"><label>1</label><p><ext-link ext-link-type="uri" xlink:href="http://regulondb.ccg.unam.mx/">http://regulondb.ccg.unam.mx/</ext-link></p></fn>
</fn-group>
</back>
</article>